Payment overview · 2025
General Payments
$239.13
9 reported records · 5 companies
Healthcare provider profile · identity verified
Garry Davis Millien, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST PALM BEACH, FL · NPI 1689628224
Verified facts
What the public records show
CMS Open Payments records show Garry Davis Millien, MD received $239.13 in general payments during 2025 across 9 reported records.
UCB, Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Yupelri.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $109.37 | 45.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $68.99 | 28.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.23 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.46 | 7.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.08 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.13 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $75.66 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $33.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 48 |
| Gabapentin | Gabapentin | 331 | 63 |
| Eliquis | Apixaban | 312 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 56 |
| Furosemide | Furosemide | 204 | 26 |
| Metformin Hcl | Metformin Hcl | 194 | 43 |
| Losartan Potassium | Losartan Potassium | 188 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 32 |
| Potassium Chloride | Potassium Chloride | 176 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 27 |
| Levetiracetam | Levetiracetam | 159 | 21 |
| Lisinopril | Lisinopril | 154 | 35 |
| Trazodone Hcl | Trazodone Hcl | 150 | 38 |
| Carvedilol | Carvedilol | 124 | 33 |
| Mirtazapine | Mirtazapine | 111 | 24 |
| Nifedipine Er | Nifedipine | 106 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 21 |
| Divalproex Sodium | Divalproex Sodium | 99 | 14 |
| Sertraline Hcl | Sertraline Hcl | 89 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 16 |
| Jardiance | Empagliflozin | 73 | 18 |
| Sucralfate | Sucralfate | 73 | 12 |
| Donepezil Hcl | Donepezil Hcl | 69 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 21 |
| Montelukast Sodium | Montelukast Sodium | 68 | 11 |
| Finasteride | Finasteride | 58 | suppressed |
| Xarelto | Rivaroxaban | 56 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 14 |
| Baclofen | Baclofen | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Lactulose | Lactulose | 45 | 17 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Omeprazole | Omeprazole | 40 | 11 |
| Ketoconazole | Ketoconazole | 39 | 13 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 15 |
| Latanoprost | Latanoprost | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 33 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Prednisone | Prednisone | 32 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Yupelri | Revefenacin | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Rytary | Carbidopa/Levodopa | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Dexamethasone | Dexamethasone | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Risperidone | Risperidone | 23 | 11 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 16 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Glucagon Emergency Kit | Glucagon | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Modafinil | Modafinil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $239.13 · 9 records | UCB, Inc. | Briviact, CAPLYTA, KEVEYIS, Nayzilam, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Yupelri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Viatris Specialty LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error